Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311144844> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4311144844 endingPage "100261" @default.
- W4311144844 startingPage "100261" @default.
- W4311144844 abstract "Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) has exhibited encouraging efficacy in an SCLC cohort in a trial evaluating S + T in pts with selected solid tumors. This study is assessing the safety, tolerability, and preliminary efficacy of S+ T+ chemotherapy (EP) as first-line regimen for SCLC pts. Here, we report the preliminary efficacy results." @default.
- W4311144844 created "2022-12-23" @default.
- W4311144844 creator A5001453412 @default.
- W4311144844 creator A5009402541 @default.
- W4311144844 creator A5014627932 @default.
- W4311144844 creator A5015246104 @default.
- W4311144844 creator A5020612964 @default.
- W4311144844 creator A5033151800 @default.
- W4311144844 creator A5042392354 @default.
- W4311144844 creator A5046131158 @default.
- W4311144844 creator A5047347350 @default.
- W4311144844 creator A5064118235 @default.
- W4311144844 creator A5077881736 @default.
- W4311144844 date "2022-12-01" @default.
- W4311144844 modified "2023-10-18" @default.
- W4311144844 title "149P A phase Ⅰb/Ⅱ trial of surufatinib plus toripalimab and etoposide (E) combined with cisplatin (P) in patients (pts) with untreated advanced small cell lung cancer (SCLC)" @default.
- W4311144844 doi "https://doi.org/10.1016/j.iotech.2022.100261" @default.
- W4311144844 hasPublicationYear "2022" @default.
- W4311144844 type Work @default.
- W4311144844 citedByCount "0" @default.
- W4311144844 crossrefType "journal-article" @default.
- W4311144844 hasAuthorship W4311144844A5001453412 @default.
- W4311144844 hasAuthorship W4311144844A5009402541 @default.
- W4311144844 hasAuthorship W4311144844A5014627932 @default.
- W4311144844 hasAuthorship W4311144844A5015246104 @default.
- W4311144844 hasAuthorship W4311144844A5020612964 @default.
- W4311144844 hasAuthorship W4311144844A5033151800 @default.
- W4311144844 hasAuthorship W4311144844A5042392354 @default.
- W4311144844 hasAuthorship W4311144844A5046131158 @default.
- W4311144844 hasAuthorship W4311144844A5047347350 @default.
- W4311144844 hasAuthorship W4311144844A5064118235 @default.
- W4311144844 hasAuthorship W4311144844A5077881736 @default.
- W4311144844 hasBestOaLocation W43111448441 @default.
- W4311144844 hasConcept C126322002 @default.
- W4311144844 hasConcept C143998085 @default.
- W4311144844 hasConcept C2776256026 @default.
- W4311144844 hasConcept C2776694085 @default.
- W4311144844 hasConcept C2778119113 @default.
- W4311144844 hasConcept C2778239845 @default.
- W4311144844 hasConcept C71924100 @default.
- W4311144844 hasConceptScore W4311144844C126322002 @default.
- W4311144844 hasConceptScore W4311144844C143998085 @default.
- W4311144844 hasConceptScore W4311144844C2776256026 @default.
- W4311144844 hasConceptScore W4311144844C2776694085 @default.
- W4311144844 hasConceptScore W4311144844C2778119113 @default.
- W4311144844 hasConceptScore W4311144844C2778239845 @default.
- W4311144844 hasConceptScore W4311144844C71924100 @default.
- W4311144844 hasLocation W43111448441 @default.
- W4311144844 hasOpenAccess W4311144844 @default.
- W4311144844 hasPrimaryLocation W43111448441 @default.
- W4311144844 hasRelatedWork W2026791198 @default.
- W4311144844 hasRelatedWork W2055244776 @default.
- W4311144844 hasRelatedWork W2077334567 @default.
- W4311144844 hasRelatedWork W2187491254 @default.
- W4311144844 hasRelatedWork W2413020017 @default.
- W4311144844 hasRelatedWork W2414573978 @default.
- W4311144844 hasRelatedWork W363598932 @default.
- W4311144844 hasRelatedWork W4206600817 @default.
- W4311144844 hasRelatedWork W4246355098 @default.
- W4311144844 hasRelatedWork W8414141 @default.
- W4311144844 hasVolume "16" @default.
- W4311144844 isParatext "false" @default.
- W4311144844 isRetracted "false" @default.
- W4311144844 workType "article" @default.